Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 3/20 | 0.50 |
| ▸ | RPS6KA5 | O75582 | 6/20 | 0.46 |
| ▸ | CDK4 | P11802 | 3/20 | 0.41 |
| ▸ | CCND1 | P24385 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562206 | 0.82 | P2RX7 (0.54) | P2RX7METRPS6KA5CDK4CCND1 | |
| SCHEMBL20665083 | 0.81 | P2RX7 (0.53) | P2RX7METRPS6KA5CDK4CCND1 | |
| SCHEMBL5676559 | 0.80 | P2RX7 (0.47) | P2RX7METRPS6KA5CDK4CCND1 | |
| SCHEMBL14409582 | 0.79 | MET (0.52) | P2RX7METRPS6KA5TDP1RPS6KA4 | |
| SCHEMBL293155 | 0.76 | TDP1 (0.72) | P2RX7TDP1LMNAALOX15TSHR | |
| SCHEMBL14409585 | 0.75 | MET (0.49) | P2RX7METRPS6KA5TDP1RPS6KA4 | |
| SCHEMBL2049592 | 0.75 | HTT (0.64) | P2RX7METRPS6KA5TDP1LMNA | |
| SCHEMBL12640059 | 0.75 | RPS6KA5 (0.52) | P2RX7METRPS6KA5TDP1RPS6KA4 | |
| SCHEMBL31609660 | 0.75 | RPS6KA5 (0.52) | P2RX7METRPS6KA5TDP1RPS6KA4 | |
| SCHEMBL4867446 | 0.73 | LTA4H (0.50) | TDP1LMNAALOX15TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | P2RX7 1839/4885MET 4093/4885RPS6KA5 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.